霍乱弧菌：黏膜疫苗设计的启示。
Vibrio cholerae: lessons for mucosal vaccine design.
机构信息
Department of Molecular Biology and Microbiology, Tufts University School of Medicine and Howard Hughes Medical Institute, Boston, MA 02111, USA.
出版信息
Expert Rev Vaccines. 2011 Jan;10(1):79-94. doi: 10.1586/erv.10.150.
Abstract
The ability of Vibrio cholerae to persist in bodies of water will continue to confound our ability to eradicate cholera through improvements to infrastructure, and thus cholera vaccines are needed. We aim for an inexpensive vaccine that can provide long-lasting protection from all epidemic cholera infections, currently caused by O1 or O139 serogroups. Recent insights into correlates of protection, epidemiology and pathogenesis may help us design improved vaccines. This notwithstanding, we have come to appreciate that even marginally protective vaccines, such as oral whole-cell killed vaccines, if widely distributed, can provide significant protection, owing to herd immunity. Further efforts are still required to provide more effective protection of young children.
摘要
霍乱弧菌在水体中持续存在的能力将继续困扰我们通过改善基础设施来根除霍乱的能力，因此需要霍乱疫苗。我们的目标是开发一种廉价的疫苗，能够为所有人提供长效保护免受目前由 O1 或 O139 血清群引起的流行霍乱感染。最近对保护相关性、流行病学和发病机制的深入了解可能有助于我们设计改良的疫苗。尽管如此，我们已经意识到，即使是保护效果稍差的疫苗，如口服全细胞灭活疫苗，如果广泛分发，也可以通过群体免疫提供显著的保护。仍然需要进一步努力，为幼儿提供更有效的保护。
相似文献
1
Vibrio cholerae: lessons for mucosal vaccine design.
Expert Rev Vaccines. 2011 Jan;10(1):79-94. doi: 10.1586/erv.10.150.
2
Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Vaccine. 2009 Feb 25;27(9):1386-92. doi: 10.1016/j.vaccine.2008.12.041. Epub 2009 Jan 13.
3
Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
PLoS One. 2019 Jun 18;14(6):e0218033. doi: 10.1371/journal.pone.0218033. eCollection 2019.
4
Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
mSphere. 2021 Aug 25;6(4):e0011421. doi: 10.1128/mSphere.00114-21. Epub 2021 Jul 7.
5
Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Vaccine. 2011 Oct 26;29(46):8285-92. doi: 10.1016/j.vaccine.2011.08.108. Epub 2011 Sep 9.
6
Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
PLoS Negl Trop Dis. 2014 May 1;8(5):e2828. doi: 10.1371/journal.pntd.0002828. eCollection 2014 May.
7
Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.
Vaccine. 2007 Jan 22;25(6):1149-55. doi: 10.1016/j.vaccine.2006.09.049. Epub 2006 Sep 29.
8
Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.
PLoS Negl Trop Dis. 2019 Aug 1;13(8):e0007634. doi: 10.1371/journal.pntd.0007634. eCollection 2019 Aug.
9
Questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003.
Vaccine. 2007 Feb 9;25(8):1353-4. doi: 10.1016/j.vaccine.2006.09.057. Epub 2006 Oct 4.
10
Comparison of O-specific polysaccharide responses in patients following infection with O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh.
mSphere. 2023 Oct 24;8(5):e0025523. doi: 10.1128/msphere.00255-23. Epub 2023 Aug 30.
引用本文的文献
1
Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice.
Bioengineering (Basel). 2022 Nov 8;9(11):662. doi: 10.3390/bioengineering9110662.
2
A dysbiotic gut microbiome suppresses antibody mediated-protection against .
iScience. 2021 Nov 14;24(12):103443. doi: 10.1016/j.isci.2021.103443. eCollection 2021 Dec 17.
3
Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of Vibrio cholerae as a vaccine candidate.
Stem Cell Res Ther. 2021 Nov 3;12(1):564. doi: 10.1186/s13287-021-02622-0.
4
Immunogenicity of cholera vaccination in children with inflammatory bowel disease.
Hum Vaccin Immunother. 2021 Aug 3;17(8):2586-2592. doi: 10.1080/21645515.2021.1884475. Epub 2021 Apr 1.
5
Human gut-associated lymphoid tissues (GALT); diversity, structure, and function.
Mucosal Immunol. 2021 Jul;14(4):793-802. doi: 10.1038/s41385-021-00389-4. Epub 2021 Mar 22.
6
Vibrio cholerae Outer Membrane Vesicles Inhibit Bacteriophage Infection.
J Bacteriol. 2018 Jul 10;200(15). doi: 10.1128/JB.00792-17. Print 2018 Aug 1.
7
Vibrio cholerae O1 secretes an extracellular matrix in response to antibody-mediated agglutination.
PLoS One. 2018 Jan 2;13(1):e0190026. doi: 10.1371/journal.pone.0190026. eCollection 2018.
8
Production of putative enhanced oral cholera vaccine strains that express toxin-coregulated pilus.
PLoS One. 2017 Apr 6;12(4):e0175170. doi: 10.1371/journal.pone.0175170. eCollection 2017.
9
The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
Clin Vaccine Immunol. 2017 Jan 5;24(1). doi: 10.1128/CVI.00470-16. Print 2017 Jan.
10
Immunity Provided by an Outer Membrane Vesicle Cholera Vaccine Is Due to O-Antigen-Specific Antibodies Inhibiting Bacterial Motility.
Infect Immun. 2016 Dec 29;85(1). doi: 10.1128/IAI.00626-16. Print 2017 Jan.
本文引用的文献
1
Topical immunization strategies.
Mucosal Immunol. 2010 Nov;3(6):545-55. doi: 10.1038/mi.2010.55. Epub 2010 Sep 22.
2
The role of secretory antibodies in infection immunity.
Nat Rev Microbiol. 2010 Sep;8(9):656-67. doi: 10.1038/nrmicro2384. Epub 2010 Aug 9.
3
Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.
Infect Immun. 2010 Oct;78(10):4402-20. doi: 10.1128/IAI.00398-10. Epub 2010 Aug 2.
4
Advances in the development of vaccines against Neisseria meningitidis.
N Engl J Med. 2010 Apr 22;362(16):1511-20. doi: 10.1056/NEJMra0906357.
5
Studies on immunity to Asiatic cholera; the O and H antigenic structure of the cholera and related vibrios.
J Infect Dis. 1946 Sep-Oct;79(2):168-97. doi: 10.1093/infdis/79.2.168.
6
Reactogenicity of live-attenuated Vibrio cholerae vaccines is dependent on flagellins.
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4359-64. doi: 10.1073/pnas.0915164107. Epub 2010 Feb 16.
7
Delivery of foreign antigens by engineered outer membrane vesicle vaccines.
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3099-104. doi: 10.1073/pnas.0805532107. Epub 2010 Jan 27.
8
Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.
Expert Rev Vaccines. 2009 Dec;8(12):1643-52. doi: 10.1586/erv.09.137.
9
Clinical outcomes in household contacts of patients with cholera in Bangladesh.
Clin Infect Dis. 2009 Nov 15;49(10):1473-9. doi: 10.1086/644779.
10
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
Lancet. 2009 Nov 14;374(9702):1694-702. doi: 10.1016/S0140-6736(09)61297-6. Epub 2009 Oct 8.
Zotero 插件